Real-World Analysis of Belumosudil in Chronic Graft-versus-Host Disease: Early Progression May Reflect Ruxolitinib Discontinuation-Associated Flare (ICBMT 2026) - Oct 8, 2026 - Abstract #OP08-2; Pres time: Sep 18, 2026; 09:10 AM - 09:20 AM; Location: Room D(2F); "Belumosudil provided meaningful disease control in heavily pretreated, multi-organ cGVHD. Early progression clustered after immediate ruxolitinib discontinuation, suggesting that transition-associated flare may confound early response assessment. Gradual tapering or temporary overlap strategies warrant further investigation."
Clinical • Real-world • Real-world evidence • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology
|
|
Jae-Ho Yoon 1; Daehun Kwag 1; Gi-June Min 1; Sung-Soo Park 1; Silvia Park 1; Sung-Eun Lee 1; Byung-Sik Cho 1; Ki-Seong Eom 1; Yoo-Jin Kim 1; Hee-Je Kim 1; Chang-Ki Min 1; Seok-Goo Cho 1
|